• Quantum BioPharma’s LUCID-MS program is built around the unmet need for MS  therapies capable of directly protecting or restoring myelin integrity that affects the loss of mobility or control of a person’s body.
  • The company announced the completion of phase 1 clinical studies involving healthy volunteers, reporting that the therapy demonstrated a favorable safety profile and was generally well tolerated.
  • Quantum BioPharma reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS.

LOS ANGELES, CA - June 9, 2026 (NEWMEDIAWIRE) - Multiple sclerosis remains one of the most challenging neurological diseases facing patients and clinicians because of its progressive nature, unpredictable course and lack of a cure. The disease affects more than 2.8 million people worldwide and approximately 1 million in the USA, and many patients continue to experience worsening disability despite the availability of numerous immune-modulating therapies. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately address the underlying neurodegeneration and myelin damage that drive long-term disease progression. Against this backdrop, Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), is advancing Lucid-MS, a patented therapeutic candidate designed to target demyelination and provide neuroprotection in multiple sclerosis to address loss of mobility and function of one’s body. 

Multiple sclerosis is a chronic autoimmune and neurodegenerative disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.